Valuation: Avenue Therapeutics, Inc.

Market Cap 923K 836K 773K 698K 1.31M 86.99M 1.36M 9.29M 3.68M 46.47M 3.46M 3.39M 148M P/E 2024
-0.22x
P/E 2025 -0.73x
Enterprise Value -1.93M -1.75M -1.62M -1.46M -2.75M -182M -2.85M -19.46M -7.72M -97.33M -7.25M -7.1M -309M EV / Sales 2024
-
EV / Sales 2025 -491,128x
Free-Float
86.49%
Yield 2024 *
-
Yield 2025 -
1 day-8.29%
1 week-34.72%
Current month-34.56%
1 month-33.33%
3 months-0.23%
6 months-30.26%
Current year-58.84%
1 week 0.28
Extreme 0.28
0.43
1 month 0.28
Extreme 0.28
0.43
Current year 0.15
Extreme 0.15
0.9
1 year 0.15
Extreme 0.15
0.96
3 years 0.15
Extreme 0.15
26.47
5 years 0.15
Extreme 0.15
2,013.75
10 years 0.15
Extreme 0.15
13,882.3
Manager TitleAgeSince
Chief Executive Officer 59 31/07/2022
Chief Executive Officer 36 30/03/2022
Investor Relations Contact - -
Director TitleAgeSince
Chairman 71 08/02/2015
Director/Board Member 69 31/07/2015
Chairman 68 06/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
02/01/26 FreeCompany 111,209 3.4934%
31/03/25 FreeCompany 33,724 1.6419%
31/12/24 OtherCompany 294,800 15.4214%
Change 5-day change 1-year change 3-year change Capi.($)
-8.29%-34.72%-63.16%-98.11% 923K
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -1.38%+0.04%+27.67%+159.96% 41B
Weighted average by Cap. -0.83%+0.20%+37.23%+162.19%

Financials

2024 2025
Net sales - 1.4 1.27 1.18 1.06 2 132.38 2.07 14.14 5.61 70.71 5.27 5.16 224.47
Net income -11.65M -10.56M -9.77M -8.81M -16.61M -1.1B -17.19M -117M -46.52M -587M -43.73M -42.8M -1.86B -2.91M -2.64M -2.44M -2.2M -4.15M -274M -4.29M -29.29M -11.61M -147M -10.92M -10.69M -465M
Net Debt -2.59M -2.35M -2.17M -1.96M -3.7M -245M -3.83M -26.12M -10.36M -131M -9.73M -9.53M -415M -2.86M -2.59M -2.39M -2.16M -4.07M -269M -4.21M -28.75M -11.4M -144M -10.71M -10.49M -456M
Projected Income Statement - Annual - Avenue Therapeutics, Inc.
Logo Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.
Employees
1
Date Price Change Volume
12/11/26 US$0.2800 -8.29% 2,828
09/11/26 US$0.3053 -28.81% 1,129

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avenue Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATXI Stock